BioCardia, Inc. (NASDAQ:BCDA) Sees Large Decrease in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 151,200 shares, a decrease of 91.7% from the August 31st total of 1,830,000 shares. Based on an average trading volume of 824,700 shares, the short-interest ratio is presently 0.2 days. Approximately 6.4% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright upped their target price on BioCardia from $4.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, August 16th.

BioCardia Stock Performance

BCDA stock traded up $0.18 on Friday, reaching $2.94. The company had a trading volume of 110,001 shares, compared to its average volume of 341,573. BioCardia has a 1 year low of $1.96 and a 1 year high of $23.25. The company’s fifty day moving average is $2.82 and its 200 day moving average is $4.16. The company has a market cap of $6.23 million, a P/E ratio of -0.41 and a beta of 1.25.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.78). BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 1,999.77%. On average, sell-side analysts predict that BioCardia will post -5.06 earnings per share for the current year.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.